Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Clinical trial NCT06305754 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06305754
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-11
- Primary completion
- 2028-08-17
- Enrollment
- 551
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.